Skip to main content

Advertisement

SpringerLink
Log in

Comment on Campana et al.: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging 2013;40:1197–205.

    Article  PubMed  CAS  Google Scholar 

  2. Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011;38:459–66.

    Article  PubMed  CAS  Google Scholar 

  3. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62.

    Article  PubMed  CAS  Google Scholar 

  4. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany

    Samer Ezziddin, Amir Sabet & Hans-Jürgen Biersack

  2. BC Cancer Agency, Vancouver, BC, Canada

    Charlotte Jane Yong-Hing

Authors
  1. Samer Ezziddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Sabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charlotte Jane Yong-Hing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans-Jürgen Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samer Ezziddin.

Additional information

A reply to this comment can be found at doi: 10.1007/s00259-013-2603-8.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ezziddin, S., Sabet, A., Yong-Hing, C.J. et al. Comment on Campana et al.: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging 41, 174–175 (2014). https://doi.org/10.1007/s00259-013-2599-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2599-0

Keywords

Search

Navigation